The performance of companies tied to flagship drugs like Viagra presents a nuanced investment landscape . While the initial boom of copyright, fueled by Viagra's extraordinary popularity, generated substantial wealth , the loss of exclusivity in key regions has introduced substantial risk . Investors are now grappling with the impact of rival medic